NCT05629845 2026-03-19
EUS-SPV
Chinese University of Hong Kong
Phase NA Recruiting
Clinical Trials
1,537 trialsNCT06354387 2026-03-19
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
China Medical University Hospital
Phase 1 Completed
NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT06077591 2026-03-18
PDO
Chinese University of Hong Kong
Phase NA Recruiting
NCT06621472 2026-03-18
Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery
Cairo University
Phase NA Recruiting
NCT07010497 2026-03-18
IAPETUS
Asan Medical Center
Phase 2 Recruiting
NCT07481032 2026-03-18
Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study
Nanfang Hospital, Southern Medical University
Phase NA Not yet recruiting
NCT07476651 2026-03-17
LASER
Seoul National University Hospital
Phase NA Not yet recruiting
NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05528952 2026-03-16
TERTIO
Centre Hospitalier Universitaire de Besancon
Phase 2 Recruiting
NCT06796114 2026-03-16
PREDICT-HCC
Centre Hospitalier Universitaire de Besancon
Phase NA Recruiting
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT05901519 2026-03-13
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT07469319 2026-03-13
BISHOP
University of Aarhus
Phase NA Recruiting
NCT05095714 2026-03-12
FASTRAK
Assistance Publique - Hôpitaux de Paris
Phase NA Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07436988 2026-03-12
ReLIVE
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 1 Not yet recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06537193 2026-03-10
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
Asan Medical Center
Phase NA Recruiting
NCT06859840 2026-03-10
LEAF
Zhejiang University
Phase NA Active not recruiting
NCT06938945 2026-03-10
Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
Peking University
Phase NA Active not recruiting
NCT07461675 2026-03-10
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland
Phase 3 Not yet recruiting
NCT04777851 2026-03-09
REPLACE
Translational Research in Oncology
Phase 3 Terminated
NCT05665348 2026-03-09
TRIPLET
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT04380545 2026-03-06
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06218420 2026-03-03
TRANSRAD-01
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT07446257 2026-03-03
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Not yet recruiting
NCT06789848 2026-02-27
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03942328 2026-02-24
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04134559 2026-02-24
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05497531 2026-02-24
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
Phase NA Recruiting
NCT07428356 2026-02-23
HALT
National Cancer Centre, Singapore
Phase NA Recruiting
NCT05488522 2026-02-20
SBRT With Atezo/Bev for HCC
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT07422753 2026-02-20
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT07116486 2026-02-19
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT05669339 2026-02-18
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT06217094 2026-02-18
Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
University of Florida
Phase 1 Withdrawn
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT07407257 2026-02-18
SBRT for Liver Tumors, Liver Metastases, and Pancreatic Tumors
Institute of Oncology Ljubljana
Phase NA Completed
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT07417397 2026-02-18
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University
Phase 3 Recruiting
NCT07417800 2026-02-18
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Not yet recruiting